177 related articles for article (PubMed ID: 16903989)
21. Factors associated with Pharmaceutical Benefits Advisory Committee decisions for listing medicines for diabetes and its associated complications.
Haque MM; Gumbie M; Gu M; Dissanayake G
Aust Health Rev; 2023 Apr; 47(2):139-147. PubMed ID: 36543249
[TBL] [Abstract][Full Text] [Related]
22. PBS medications--improving access for Aboriginal and Torres Strait Islander peoples.
Couzos S
Aust Fam Physician; 2005 Oct; 34(10):841-4. PubMed ID: 16217569
[TBL] [Abstract][Full Text] [Related]
23. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
Robertson J; Walkom EJ; Henry DA
Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
[TBL] [Abstract][Full Text] [Related]
24. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004.
Harris AH; Hill SR; Chin G; Li JJ; Walkom E
Med Decis Making; 2008; 28(5):713-22. PubMed ID: 18378939
[TBL] [Abstract][Full Text] [Related]
25. The Australian model of immunization advice and vaccine funding.
Nolan TM
Vaccine; 2010 Apr; 28 Suppl 1():A76-83. PubMed ID: 20413003
[TBL] [Abstract][Full Text] [Related]
26. Australian managed entry scheme: a new manageable process for the reimbursement of new medicines?
Wonder M; Backhouse ME; Sullivan SD
Value Health; 2012 May; 15(3):586-90. PubMed ID: 22583471
[TBL] [Abstract][Full Text] [Related]
27. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
Scuffham PA; Whitty JA; Mitchell A; Viney R
Pharmacoeconomics; 2008; 26(4):297-310. PubMed ID: 18370565
[TBL] [Abstract][Full Text] [Related]
28. Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea.
Bae G; Bae EY; Bae S
Health Policy; 2015 May; 119(5):577-87. PubMed ID: 25666339
[TBL] [Abstract][Full Text] [Related]
29. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
Henry D
Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
[TBL] [Abstract][Full Text] [Related]
30. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
Wong CKH; Wu O; Cheung BMY
Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
[TBL] [Abstract][Full Text] [Related]
31. Moral hazard and prescription medicine use in Australia--the patient perspective.
Doran E; Robertson J; Henry D
Soc Sci Med; 2005 Apr; 60(7):1437-43. PubMed ID: 15652677
[TBL] [Abstract][Full Text] [Related]
32. Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia.
Phan YHL; De Abreu Lourenco R; Haas M; van der Linden N
Mult Scler Relat Disord; 2018 Oct; 25():144-149. PubMed ID: 30077086
[TBL] [Abstract][Full Text] [Related]
33. Generic drugs: international trends and policy developments in Australia.
Lofgren H
Aust Health Rev; 2004; 27(1):39-48. PubMed ID: 15362295
[TBL] [Abstract][Full Text] [Related]
34. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
[TBL] [Abstract][Full Text] [Related]
35. Review of a decision by the Medical Services Advisory Committee based on health technology assessment of an emerging technology: the case for remotely assisted radical prostatectomy.
O'Malley SP; Jordan E
Int J Technol Assess Health Care; 2007; 23(2):286-91. PubMed ID: 17493316
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).
George B; Harris A; Mitchell A
Pharmacoeconomics; 2001; 19(11):1103-9. PubMed ID: 11735677
[TBL] [Abstract][Full Text] [Related]
37. Drug reimbursement policies in Canada--need for improved access to critical therapies.
LeLorier J; Bell A; Bougher DJ; Cox JL; Turpie AG
Ann Pharmacother; 2008 Jun; 42(6):869-73. PubMed ID: 18477735
[TBL] [Abstract][Full Text] [Related]
38. Drug policy down under: Australia's pharmaceutical benefits scheme.
Duckett SJ
Health Care Financ Rev; 2004; 25(3):55-67. PubMed ID: 15229996
[TBL] [Abstract][Full Text] [Related]
39. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
Morgan S; McMahon M; Greyson D
Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
[TBL] [Abstract][Full Text] [Related]
40. Improving access to medicines in urban, regional and rural Aboriginal communities--is expansion of Section 100 the answer?
Stoneman J; Taylor SJ
Rural Remote Health; 2007; 7(2):738. PubMed ID: 17590140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
